Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION-9, ORION-10 and ORION-11 Phase 3 randomized trials.
Lawrence Alan LeiterFrederick J RaalGregory G SchwartzWolfgang KoenigKausik K RayUlf LandmesserJackie HanLorena Garcia CondeR Scott WrightPublished in: Diabetes, obesity & metabolism (2024)
Inclisiran provided substantial and sustained LDL cholesterol lowering across glycaemic/BMI strata, with a modest excess of transient mild-to-moderate TEAEs at the injection site.